|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100042255 |
|
最近更新日期: Date of Last Refreshed on: |
2021-04-16 18:15:55 |
|
注册时间: Date of Registration: |
2021-01-17 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
干晓琴医师:请联系我们上传正式版伦理审批文件。 基于快速康复外科策略和单孔腹腔镜技术开展子宫全切日间手术的可行性及安全性分析 |
|
Public title: |
Analysis of the feasibility and safety of day surgery for total hysterectomy based on enhanced recovery after surgery strategies and single port laparoscopic techniques |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于快速康复外科策略和单孔腹腔镜技术开展子宫全切日间手术的可行性及安全性分析 |
|
Scientific title: |
Analysis of the feasibility and safety of day surgery for total hysterectomy based on enhanced recovery after surgery strategies and single port laparoscopic techniques |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
干晓琴 |
研究负责人: |
干晓琴 |
|
Applicant: |
Xiao-Qin Gan |
Study leader: |
Xiao-Qin Gan |
|
申请注册联系人电话: Applicant telephone: |
+86 13980672233 |
研究负责人电话:
Study leader's |
+86 13980672233 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
316112248@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
316112248@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
成都市青羊区东城根下街24号 |
研究负责人通讯地址: |
成都市青羊区东城根下街24号 |
|
Applicant address: |
24 Dongchenggenxia Street, Qingyang District, Chengdu |
Study leader's address: |
24 Dongchenggenxia Street, Qingyang District, Chengdu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
电子科技大学医学院附属妇女儿童医院,成都市妇女儿童中心医院 |
||
|
Applicant's institution: |
Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China |
||
|
研究负责人所在单位: |
电子科技大学医学院附属妇女儿童医院,成都市妇女儿童中心医院 |
||
|
Affiliation of the Leader: |
Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
科研伦理预审【2021】6 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
成都市妇女儿童中心医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Chengdu Women's and Children's Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-01-14 00:00:00 | ||
|
伦理委员会联系人: |
唐丽娟 |
||
|
Contact Name of the ethic committee: |
Li-Juan Tang |
||
|
伦理委员会联系地址: |
成都市青羊区日月大道一段1617号 |
||
|
Contact Address of the ethic committee: |
1617 First Section of Riyue Avenue, Chengdu, Sichuan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
电子科技大学医学院附属妇女儿童医院,成都市妇女儿童中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
成都市青羊区日月大道一段1617号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1617 First Section of Riyue Avenue, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
成都市妇女儿童中心医院新技术项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
New technology project of Chengdu Women's and Children's Central Hospital |
||||||||||||||||||||||
|
研究疾病: |
妇科疾病 |
||||||||||||||||||||||
|
Target disease: |
Gynecological diseases |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究拟纳入72例因妇科疾病需要行全子宫切除术的患者开展日间手术,采用ERAS策略和LESS/V-NOTES技术,收集患者手术时间,术中出血量,是否中转腹腔镜多孔或开腹,围手术期并发症,是否转入普通病房,是否非计划重返手术、术后首次排气时间、术后首次下床活动时间、术后首次进食时间、疼痛视觉模拟评分、住院时间、是否延迟出院、患者生活质量评分、术后30天再次住院率、病人满意度、住院费用等指标,评估开展全子宫切除日间手术的可行性及安全性,为国家卫健委将全子宫切除手术纳入日间手术管理的政策提供实践依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study intends to enroll 72 patients who need total hysterectomy due to gynecological diseases to undergo day surgery. The ERAS strategy and LESS/V-NOTES technology are used to collect the operation time, intraoperative blood loss, and whether to switch to laparoscopic surgery. Abdomen, perioperative complications, whether to be transferred to the general ward, whether to return to the operation unplanned, the first postoperative exhaust time, the first postoperative time to get out of bed, the first postoperative eating time, pain visual analog score, hospital stay, Whether to delay discharge from the hospital, the patients quality of life score, the 30-day postoperative rehospitalization rate, patient satisfaction, hospitalization costs and other indicators, to evaluate the feasibility and safety of day surgery for total hysterectomy, and to provide a practical basis for the National Health Commission to incorporate total hysterectomy into day surgery management. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)年龄45~65岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1) Aged 45-65 years; |
||||||||||||||||||||||
|
排除标准: |
1)体温 > 37.4℃; |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Body temperature > 37.4 degrees C; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2023-01-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-01-18 00:00:00 至 To 2023-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机对照研究 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Non-randomized controlled study |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内通过ResMan系统共享原始数据, http://www.medresman.org.cn。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data will be shared through the ResMan system within 6 months after the test is completed, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1. 病例记录表,2. 电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Case Record Form (CRF);2.Electronic Data Capture(EDC). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |